Balyasny Asset Management
STLN

Balyasny Asset Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Balyasny Asset Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.61M Sell
1,826,370
-692,067
-27% -$2.12M 0.01% 1325
2025
Q4 		$8.97M Buy
2,518,437
+100
+0% +$371 0.01% 1076
2025
Q3 		$8.79M Hold
2,518,337
– – 0.01% 1118
2025
Q2 		$5.16M Buy
2,518,337
+371,005
+17% +$928K 0.01% 1278
2025
Q1 		$2.45M Buy
2,147,332
+421,770
+24% +$327K ﹤0.01% 1611
2024
Q4 		$533K Hold
1,725,562
– – ﹤0.01% 2175
2024
Q3 		$564K Hold
1,725,562
– – ﹤0.01% 2210
2024
Q2 		$794K Hold
1,725,562
– – ﹤0.01% 1880
2024
Q1 		$2.73M Buy
1,725,562
+472,525
+38% +$898K ﹤0.01% 1447
2023
Q4 		$2.56M Buy
1,253,037
+815,458
+186% +$1.41M ﹤0.01% 1378
2023
Q3 		$613K Buy
+437,579
New +$453K ﹤0.01% 1696
2022
Q2 		– Sell
-10,873
Closed -$78K – 3186
2022
Q1 		$78K Buy
+10,873
New +$73.4K ﹤0.01% 2180

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Balyasny Asset Management's STLN Position: Q1 2026 in Review

Balyasny Asset Management reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 27% in Q1 2026, selling an estimated $2.12M and leaving 1,826,370 shares worth $5.61M. The position accounts for 0.01% of the portfolio, ranked #1325.

Balyasny Asset Management first reported a position in STLN in Q1 2022 and has held it in 12 quarters since. The position peaked at $8.97M in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Balyasny Asset Management held 1,826,370 shares of Starling Oncology Institute, Inc. Common Stock worth $5.61M as of Q1 2026.
  • Balyasny Asset Management sold 692,067 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $2.12M.
  • Starling Oncology Institute, Inc. Common Stock made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1325 holding.
  • Balyasny Asset Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2022 and has held it in 12 quarters since.
  • Balyasny Asset Management's Starling Oncology Institute, Inc. Common Stock position peaked at $8.97M in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.